197 related articles for article (PubMed ID: 34180288)
21. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
[TBL] [Abstract][Full Text] [Related]
22. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
23. OUTCOMES OF NONCONFLUENT DIODE LASER PANRETINAL PHOTOCOAGULATION FOR AGGRESSIVE POSTERIOR RETINOPATHY OF PREMATURITY AFTER INTRAVITREAL BEVACIZUMAB.
Mammo DA; Rubino SM; Quiram PA
Retina; 2021 Apr; 41(4):706-710. PubMed ID: 32796444
[TBL] [Abstract][Full Text] [Related]
24. Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes.
Futamura Y; Asami T; Nonobe N; Kachi S; Ito Y; Sato Y; Hayakawa M; Terasaki H
Jpn J Ophthalmol; 2015 Nov; 59(6):378-88. PubMed ID: 26265249
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
[TBL] [Abstract][Full Text] [Related]
26. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
27. PROPHYLACTIC PERIPHERAL LASER AND FLUORESCEIN ANGIOGRAPHY AFTER BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY.
Garcia Gonzalez JM; Snyder L; Blair M; Rohr A; Shapiro M; Greenwald M
Retina; 2018 Apr; 38(4):764-772. PubMed ID: 28267112
[TBL] [Abstract][Full Text] [Related]
28. Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP.
Sen P; Agarwal AAK; Bhende P; Ganesan S
Int Ophthalmol; 2022 Jan; 42(1):95-101. PubMed ID: 34415476
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series.
Dani C; Frosini S; Fortunato P; Bertini G; Pratesi S; Pollazzi L; Caputo R; La Torre A
J Matern Fetal Neonatal Med; 2012 Nov; 25(11):2194-7. PubMed ID: 22506618
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity.
Gunay M; Celik G; Gunay BO; Aktas A; Karatekin G; Ovali F
Arq Bras Oftalmol; 2015; 78(5):300-4. PubMed ID: 26466229
[TBL] [Abstract][Full Text] [Related]
32. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
Chung EJ; Kim JH; Ahn HS; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
[TBL] [Abstract][Full Text] [Related]
33. Characteristic clinical features associated with aggressive posterior retinopathy of prematurity.
Ahn YJ; Hong KE; Yum HR; Lee JH; Kim KS; Youn YA; Park SH
Eye (Lond); 2017 Jun; 31(6):924-930. PubMed ID: 28234354
[TBL] [Abstract][Full Text] [Related]
34. Combined Vitrectomy and Anti-VEGF Treatment for Stage 4 Retinopathy of Prematurity With Extensive Neovascular Proliferation.
Chandra P; Kumawat D; Agarwal D; Chawla R
J Pediatr Ophthalmol Strabismus; 2020 Jan; 57(1):61-66. PubMed ID: 31972043
[TBL] [Abstract][Full Text] [Related]
35. Longitudinal Change of Refractive Error in Retinopathy of Prematurity Treated With Intravitreal Bevacizumab or Laser Photocoagulation.
Wiecek E; Akula JD; Vanderveen DK; Mantagos IS; Wu C; Curran AL; De Bruyn H; Peterson B; Fulton AB
Am J Ophthalmol; 2022 Aug; 240():252-259. PubMed ID: 35367438
[TBL] [Abstract][Full Text] [Related]
36. Which dose of bevacizumab is more effective for the treatment of aggressive posterior retinopathy of prematurity: lower or higher dose?
Dikci S; Ceylan OM; Demirel S; Yılmaz T
Arq Bras Oftalmol; 2018; 81(1):12-17. PubMed ID: 29538588
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity.
Gangwe AB; Agrawal D; Gangrade AK; Parchand SM; Agrawal D; Azad RV
Indian J Ophthalmol; 2021 Aug; 69(8):2171-2176. PubMed ID: 34304203
[TBL] [Abstract][Full Text] [Related]
38. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
Kıran Yenice E; Petriçli İS; Kara C
Int Ophthalmol; 2023 Jul; 43(7):2197-2202. PubMed ID: 36522564
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Intravitreal Bevacizumab and Diode Laser Photocoagulation for Treatment-Warranted Retinopathy of Prematurity.
Chen TA; Schachar IH; Moshfeghi DM
Ophthalmic Surg Lasers Imaging Retina; 2018 Feb; 49(2):126-131. PubMed ID: 29443362
[TBL] [Abstract][Full Text] [Related]
40. A Comparison of Respiratory Outcomes after Treating Retinopathy of Prematurity with Laser Photocoagulation or Intravitreal Bevacizumab.
Barry GP; Tauber KA; Greenberg S; Lajoie J; Afroze F; Oechsner H; Finucane E; Binenbaum G
Ophthalmol Retina; 2020 Dec; 4(12):1202-1208. PubMed ID: 32512055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
